Realta Investment Advisors Takes $1.16 Million Position in Amgen Inc. $AMGN

Realta Investment Advisors purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 3,298 shares of the medical research company’s stock, valued at approximately $1,160,000.

Several other hedge funds have also recently bought and sold shares of the business. High Note Wealth LLC grew its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares in the last quarter. TAGStone Capital Inc. increased its holdings in shares of Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after purchasing an additional 28 shares during the period. Verus Capital Partners LLC lifted its position in shares of Amgen by 2.3% in the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after purchasing an additional 28 shares in the last quarter. Destination Wealth Management lifted its position in shares of Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after purchasing an additional 29 shares in the last quarter. Finally, Breakwater Capital Group boosted its holdings in shares of Amgen by 1.4% during the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after purchasing an additional 29 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on AMGN shares. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a research report on Thursday, June 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. UBS Group upped their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, April 13th. Finally, Leerink Partners reiterated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.42.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.85% of the company’s stock.

Amgen Trading Up 1.6%

NASDAQ:AMGN opened at $358.61 on Friday. The company has a market capitalization of $193.54 billion, a P/E ratio of 24.96, a P/E/G ratio of 3.60 and a beta of 0.42. The stock’s 50 day moving average price is $340.70 and its 200 day moving average price is $346.20. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.